ipecac syrup regulatory history n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Ipecac Syrup: Regulatory History PowerPoint Presentation
Download Presentation
Ipecac Syrup: Regulatory History

Loading in 2 Seconds...

play fullscreen
1 / 17

Ipecac Syrup: Regulatory History - PowerPoint PPT Presentation


  • 130 Views
  • Uploaded on

Ipecac Syrup: Regulatory History . Nonprescription Drugs Advisory Committee Meeting Arlene Solbeck, M.S. Interdisciplinary Scientist, Division of OTC Drug Products. Center for Drug Evaluation and Research. Content. The OTC Drug Monograph Process Regulatory History for Ipecac Syrup

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Ipecac Syrup: Regulatory History' - locke


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
ipecac syrup regulatory history

Ipecac Syrup: Regulatory History

Nonprescription Drugs

Advisory Committee Meeting

Arlene Solbeck, M.S.

Interdisciplinary Scientist, Division of OTC Drug Products

Center for Drug Evaluation and Research

content
Content
  • The OTC Drug Monograph Process
  • Regulatory History for Ipecac Syrup
  • Highlights from the 1985 Tentative Final Monograph
    • Proposed Labeling
  • Some Final Monograph Issues
  • Summary
otc drug monograph process the otc drug review
OTC Drug Monograph Process(The OTC Drug Review)
  • Established in 1972
  • Active ingredient based review
      • ingredient: ipecac
      • class: poison treatment
  • Final Monograph states conditions for marketing and required labeling
  • Ipecac syrup is regulated under the monograph process
otc drug monograph process 3 phases
OTC Drug Monograph Process(3 Phases)
  • Advance Notice of Proposed Rulemaking (ANPR) Advisory Review Panel Report
  • Tentative Final Monograph (TFM)
  • Final Monograph (FM)
  • The rulemaking for ipecac syrup is in the Final Monograph phase
fda s first regulation for ipecac syrup pre otc drug review
FDA’s First Regulation for Ipecac SyrupPre-OTC Drug Review
  • In 1965, “Ipecac Syrup; warnings and directions for OTC sale” was added as a new regulation (now codified at 21 CFR 201.308).
    • immediate availability of ipecac syrup for use in poisoning emergencies necessitated quick and easy availability for consumers.
    • recommended by the Am. Acad. of Pediatrics, Am. Assoc. of Poison Control Centers, AMA, and the Medical Advisory Board of the FDA.
    • FDA Commissioner: “ipecac syrup in 1 fluid ounce containers should be permitted to be sold without prescription for emergency use to cause vomiting in poisoning”.
fda s first regulation for ipecac syrup pre otc drug review1

Before using, call physician,

the Poison Control Center,

or hospital emergency room

immediately

for advice

FDA’s First Regulation for Ipecac SyrupPre-OTC Drug Review

Ipecac Syrup

Warnings and Directions

Principal Display Panel

Labeling

  • Usual dosage: 15 mL in persons over 1 year of age
  • Not to be used in unconscious persons
  • Not to be administered after certain kinds of poisons
    • strychnine
    • corrosives
    • petroleum distillates
regulatory history monograph process
Regulatory History- Monograph Process
  • Advance Notice of Proposed Rulemaking ANPR (1975)
    • Advisory Review Panel on OTC Laxative, Antidiarrheal, Emetic, and Antiemetic Drug Products (LAEA Panel)
    • LAEA Panel classified ipecac syrup as a Category I (safe and effective) emetic
  • Tentative Final Monograph (1978)
    • FDA’s tentative conclusions on comments submitted in response to the 1975 Panel’s report
      • infants under 1 year - 5 to 10 mL followed by 4-8 ounces liquid
      • infants over 1 year, children, adults - 15mL followed by 8-16 ounces liquid
      • do not administer milk or carbonated beverages with ipecac
      • administer second dose after 20 min. if vomiting doesn’t occur
      • do not administer in semiconscious or unconscious persons
      • Drug Interaction Precaution
regulatory history monograph process con t
Regulatory History- Monograph Process (con’t)
  • Advance Notice of Proposed Rulemaking ANPR (1982)
    • Advisory Review Panel on OTC Miscellaneous Internal Drugs (MI Panel) reviewed kit containing ipecac and activated charcoal
    • MI Panel classified ipecac syrup and activated charcoal as Category 1 (safe and effective) to treat acute toxic ingestion
  • Tentative Final Monograph (1985)
    • Based on the recommendations of both the LAEA and MI Panels and comments on those reports
    • Contains FDA’s tentative conclusions and proposed labeling on OTC poison treatment drugs
1985 tentative final monograph principal display panel labeling
1985 Tentative Final MonographPrincipal Display Panel Labeling

Ipecac Syrup

If possible call a Poison Control Center, emergency medical facility, or health professional for help before using this product.

If help cannot be reached quickly, follow the directions.

Read the warnings and directions as soon as you buy this product.

Insert emergency phone numbers in space provided on the label.

30 mL

1985 tentative final monograph directions
1985 Tentative Final Monograph - Directions
  • Proposed Dosages
    • adults and children 12 years and older: 30 mL followed by 8-16 ounces liquid
    • children 1-under 12 years: 15 mLfollowed by 8-16 ounces liquid
    • children 6 mo. to under 1 year: 5 mLfollowed by 4-8 ounces liquid
    • children under 6 months: not recommended
  • Proposed Directions
    • water or other clear liquids to be administered following ipecac; milk should not be given
    • repeat dosage if vomiting does not occur within 30 min.
    • keep patients active and moving
1985 tentative final monograph warnings
1985 Tentative Final Monograph - Warnings
  • Proposed Warnings
    • do not use in persons who are not fully conscious
    • do not use this product if turpentine, corrosives (such as alkalies (lye) and strong acids), or petroleum distillates (such as kerosene, gasoline, paint thinner or furniture polish) have been ingested.
    • do not administer milk
  • Poison Treatment Kit
    • Drug Interaction Precaution: Do not give activated charcoal until after the patient has vomited, unless directed by a health professional.
sample label
Sample Label

SAFETY SEALED

XXXXX

ACTIVE INGREDIENTS; Ipecac

F.E. ALSO CONTAINS: Glycerin,

Sodium Benzoate, Sucrose,

Purified Water. WARNING: Do

not use if shrink band around cap

imprinted “Sealed For Your

Protection” is broken or missing.

INDICATIONS: For emergency

use to cause vomiting of

swallowed poisons. WARNING:

Do not use in persons who are

not fully conscious. Do not use

this product, unless directed by

a health professional, if turpentine,

corrosives, such as alkalies (lye)

and strong acids, or petroleum

distillates, such as kerosene,

gasoline, paint thinner, cleaning

fluid, or furniture polish, have been

ingested. Do not administer milk

with this product.

INTERACTION PRECAUTION:

Activated charcoal will absorb

ipecac syrup. Do not give

activated charcoal until after the

patient has vomited, unless

directed by a health professional.

DIRECTIONS: Adults and children 12

years of age and over: oral dosage is

2 tablespoonfuls (30 milliliters or 1 bottle)

followed by 1-2 glasses (8-16 ozs.)

of water or other clear liquid as directed

by a health professional. Children 1 to

under 12 years of age: oral dosage is

1 tablespoonful (15 milliliters or 1/2 bottle)

followed by 1 to 2 glasses or water or

other clear liquid or as directed by a

health professional. Children 6 months

to under 1 year of age: oral dosage is

1 teaspoonful (5 milliliters) followed by

1/2 to 1 glass (4-8 ozs.) of water or other

clear liquid or as directed by a health

professional. Children under 6 months

of age: Do not administer unless directed

by a health professional. If vomiting does

not occur within 30 minutes, repeat the

dose. If previous attempts to contact a

poison control center, emergency medical

facility, or health professional were

unsuccessful, continue trying. Keep

patient active and moving. Save the

container of poison.

IPECAC SYRUP USP

EMETIC ALCOHOL 1.75%

POISON

FIRST AID

If possible, call a Poison Control Center, emergency facility

or health professional for help before using this product. If

help cannot be reached quickly, follow the directions on this

label. Read the warnings and directions as soon as you buy

this product. Insert emergency phone number(s) in space

provided on the label_____________________________

Contents 1 FL.OZ. (30 mL)

comments after the 1985 tentative final monograph published
Comments After the 1985 Tentative Final Monograph Published
  • FDA received comments from
    • 6 poison control centers
    • 6 hospitals
    • 7 medical schools
    • 3 trade associations
    • 5 manufacturers
    • 3 law firms
    • 14 individuals
  • Comments for OTC availability
    • OTC availability of ipecac syrup for treating accidental poisonings in the public interest medically and financially
comments con t
Comments (con’t)
  • Comments about safety aspects of using ipecac
    • concern for proper management of poisoning
    • children under 1 year of age may have an increased risk for aspiration and dehydration
    • potential risks of ipecac syrup induced vomiting in the elderly
    • concern that ipecac syrup not be misused or abused
recent developments post 1985 tentative final monograph
Recent DevelopmentsPost - 1985 Tentative Final Monograph
  • Medical literature and some poison control and clinical toxicology societies indicate the safety and efficacy of ipecac syrup should be reevaluated
  • Clinical studies question benefit of ipecac
recent developments con t
Recent Developments (con’t)
  • Recommends reevaluation of ipecac’s benefit
    • American Academy of Clinical Toxicology - 1997 position statement
    • European Association of Poison Centers & Clinical Toxicologists - 1997 position statement
    • American Board of Applied Toxicology (endorses 1997 statement)
    • Canadian Association of Poison Control Centers (endorses 1997 statement)
  • Recommends ipecac for accidental poisonings
    • American College of Emergency Physicians
    • American Medical Association
summary
Summary
  • Poison Treatment rulemaking is in the Final Monograph stage.
  • Ipecac syrup and activated charcoal are the only two ingredients classified as Category I (safe and effective) for OTC poison treatment.
  • Should ipecac syrup remain OTC?